{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-041578","form_type":"8-K/A","ticker":"SKIN","cik":"0001818093","company_name":"SkinHealth Systems Inc.","filed_at":"2023-12-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:30.644202+00:00","generated_at":"2026-06-07T12:59:36.366740+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Beauty Health finalizes separation with former CEO Stanleick; 58,536 shares vested, 18-month non-compete","bullets":["CEO Andrew Stanleick terminated without cause effective Nov 19, 2023; signed Separation Letter on Dec 8, 2023.","Severance includes 18 months base salary, prorated target bonus, COBRA reimbursements, and outplacement up to $15,000.","Retention award of 58,536 shares of Class A common stock fully vested within 15 days of signing release.","18-month non-competition covenant barring work with microdermabrasion/hydrodermabrasion machine manufacturers.","Mutual non-disparagement agreed; Stanleick remains bound by existing confidentiality obligations."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-041578","json":"https://secwatch.observer/filing/0001628280-23-041578.json","markdown":"https://secwatch.observer/filing/0001628280-23-041578.md","text":"https://secwatch.observer/filing/0001628280-23-041578.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023041578/0001628280-23-041578-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023041578/skin-20231110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T12:59:36.366740+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"12b5863d4e","claim":"Andrew Stanleick departed as Chief Executive Officer at SkinHealth Systems Inc..","evidence_excerpt":"Mr. Stanleick’s termination from his position as Chief Executive Officer of the Company without cause","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1818093/000162828023041578/0001628280-23-041578-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"terminated without cause"},{"label":"Role","value":"Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}